# Second-Line Irinotecan vs. ILF for AGC

> **NCT00509964** · PHASE2 · UNKNOWN · sponsor: **Gachon University Gil Medical Center** · enrollment: 50 (estimated)

## Conditions studied

- Stomach Neoplasm
- Metastatic
- Second-Line

## Interventions

- **DRUG:** irinotecan
- **DRUG:** ILF

## Key facts

- **NCT ID:** NCT00509964
- **Lead sponsor:** Gachon University Gil Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-05
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2007-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509964, "Second-Line Irinotecan vs. ILF for AGC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00509964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*